A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

3期 已完成 NCT05633355

摘要

The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.

Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)

From first dose of trial intervention to end of trial; median (min, max) duration was 52.1 (2.0, 70.1) weeks · Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
• Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
• A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
• A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen
• BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort — Women's College Hospital

全部试验